A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Necitumumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 11 Aug 2017 The trial was completed in Belgium.
- 21 Nov 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Nov 2016 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.